Pyxis Oncology Inc (PYXS) ニュース

Form 8-K - Current report

Form 8-K - Current report

Pyxis Oncology Expands Board of Directors with Appointment of Michael A. Metzger

BOSTON, June 10, 2024 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: “PYXS”), a clinical stage company...

Form 4 - Statement of changes in beneficial ownership of securities

Pyxis Oncology to Participate in a Fireside Chat at the Jefferies Global Healthcare Conference

BOSTON, May 30, 2024 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical stage company...

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

Pyxis Oncology Provides Corporate Update and Reports Financial Results for First Quarter 2024

PYX-201 Phase 1 trial clinical readout on track for fall of 2024 Executive Leadership Team expanded with the...

Pyxis Oncology to Present at the RBC Capital Markets Global Healthcare Conference

BOSTON, May 09, 2024 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical stage company...

Pyxis Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BOSTON, March 28, 2024 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical stage company...

Pyxis Oncology Obtains $8 Million Payment for the Sale of Royalty Rights

Non-dilutive funding to support development of first-in-concept lead Antibody-Drug Conjugate (ADC) asset...

Pyxis Oncology Provides Corporate Update and Reports Financial Results for Fourth Quarter and Full Year 2023

PYX-201 Phase 1 Part 1 trial progressing with initial data expected in the fall of 2024 PYX-106 Phase 1 trial...

Pyxis Oncology Expands Board of Directors with Appointment of Santhosh Palani, Ph.D., CFA

BOSTON, March 13, 2024 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: “PYXS”), a clinical stage company...

Form SC 13G - Statement of acquisition of beneficial ownership by individuals

Pyxis Oncology to Present at Leerink Global Biopharma Conference 2024

BOSTON, March 07, 2024 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical stage company...